Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs VAC 3S (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Sponsors InnaVirVax
- 07 Jun 2017 Biomarkers information updated
- 29 Sep 2016 This trial has been completed in Germany (End date: 2016-09-01) as per European Clinical Trials Database record.
- 23 Jun 2016 This trial was completed in Spain according to the European Clinical Trials Database.